TIDMGSK
RNS Number : 4007U
GlaxoSmithKline PLC
29 July 2020
Issued: 29(th) July 2020, London, UK and Paris, France
GlaxoSmithKline plc ("GSK")
Sanofi and GSK agree with the UK government to supply up to 60
million doses of COVID-19 vaccine
-- Agreement relates to vaccine candidate using Sanofi's
recombinant protein-based technology combined with GSK's pandemic
adjuvant system
-- Both companies are committed to making their COVID-19 vaccine
candidate affordable and available globally
Sanofi and have reached an agreement, subject to final contract,
with the UK government for the supply of up to 60 million doses of
a COVID-19 vaccine. The vaccine candidate, developed by Sanofi in
partnership with GSK, is based on the recombinant protein-based
technology used by Sanofi to produce an influenza vaccine, and
GSK's established pandemic adjuvant technology.
"With our partner GSK, we are pleased to cooperate with the UK
government as well as several other countries and global
organizations as part of our ongoing efforts to develop a safe and
effective vaccine and make it available as quickly as possible. We
greatly appreciate the UK government's support of this shared
vision," said Thomas Triomphe, Executive Vice President and Global
Head of Sanofi Pasteur.
Roger Connor, President of GSK Vaccines added, "We believe that
this adjuvanted vaccine candidate has the potential to play a
significant role in overcoming the COVID-19 pandemic, both in the
UK and around the world. We thank the UK Government for
confirmation of purchasing intent, which supports the significant
investment we are already making as a company to scale up
development and production of this vaccine."
Sanofi is leading the clinical development and registration of
the COVID-19 vaccine and expects a Phase 1/2 study to start in
September, followed by a Phase 3 study by the end of 2020. If the
data are positive, regulatory approval could be achieved by the
first half of 2021. In parallel, Sanofi and GSK are scaling up
manufacturing of the antigen and adjuvant to produce up to one
billion doses per year overall.
UK Business Secretary Alok Sharma said: "Our scientists and
researchers are racing to find a safe and effective vaccine at a
speed and scale never seen before. While this progress is truly
remarkable, the fact remains that there are no guarantees.
"In the meantime, it is important that we secure early access to
a diverse range of promising vaccine candidates, like GSK and
Sanofi, to increase our chances of finding one that works so we can
protect the public and save lives."
Kate Bingham, Chair of the UK Government's Vaccines Taskforce,
said: "Through this agreement with GSK and Sanofi, the Vaccine
Taskforce can add another type of vaccine to the three different
types of vaccine we have already secured.
"This diversity of vaccine types is important because we do not
yet know which, if any, of the different types of vaccine will
prove to generate a safe and protective response to COVID-19.
Whilst this agreement is very good news, we mustn't be complacent
or over optimistic.
"The fact remains we may never get a vaccine and if we do get
one, we have to be prepared that it may not be a vaccine which
prevents getting the virus, but rather one that reduces
symptoms."
Sanofi and GSK are committed to making the vaccine available
globally
Active discussions on supply of the vaccine are ongoing with
global organizations, the US and the EU Commission - with France
and Italy on the negotiation team. The partners plan to provide a
significant portion of total worldwide available supply capacity in
2021/22, to the global initiative " Access to COVID -- 19 Tools
(ACT) Accelerator " , a global collaboration of leaders of
governments, global health organizations, businesses and
philanthropies to accelerate development, production, and equitable
access to COVID-19 tests, treatments, and vaccines.
GSK commitment to tackling COVID-19
GSK is collaborating with companies and research groups across
the world working on promising COVID-19 vaccine candidates through
the use of our innovative vaccine adjuvant technology. The use of
an adjuvant is of particular importance in a pandemic situation
since it may reduce the amount of vaccine protein required per
dose, allowing more vaccine doses to be produced and therefore
contributing to protecting more people. GSK does not expect to
profit from COVID-19 vaccines during the pandemic phase, and will
invest any short-term profit in coronavirus related research and
long-term pandemic preparedness, either through GSK internal
investments or with external partners.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Simon Moore +44 (0) 20 8047 (London)
5502
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
Danielle Smith +44 (0) 20 8047 (London)
0932
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCPPUWAMUPUPGR
(END) Dow Jones Newswires
July 29, 2020 02:00 ET (06:00 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
